Air Transat Reaches Tentative Agreement With Pilots, Avoids Strike and Restores Normal Operations 
Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny 
EU Court Cuts Intel Antitrust Fine to €237 Million Amid Long-Running AMD Dispute 
Wall Street Futures Slip as Oracle Earnings Miss Reignites AI Spending Concerns 
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 
Global Markets Slide as Tech Stocks Sink, Yields Rise, and AI Concerns Deepen 
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium 
Brazil Holds Selic Rate at 15% as Inflation Expectations Stay Elevated 
Nvidia Develops New Location-Verification Technology for AI Chips 
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates 
Asian Currencies Steady as Fed Delivers Hawkish Rate Cut; Aussie and Rupee Under Pressure 
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market 
Gold Prices Hold Firm as Markets Await Fed Rate Cut; Silver Surges to Record High 
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
An Abbott Laboratories processing plant in Sturgis, Mich being investigated for cases of infant illness is being allowed to release some product that was processed before it was shut down.
Certain goods designed for infants and people with specific medical issues will be given out for free.
Abbott officials claimed they're doing it at the FDA's request to help with shortages of these specialty feeding items.
After a recall of Similac infant formula and other products in February, the Sturgis plant was forced to shut down. Cronobacter bacteria had infected many infants, one of whom died; cronobacter was identified in their systems and the formula they had drunk. Cronobacter bacteria were discovered in the factory during an inspection.
However, further examination revealed that the cronobacter strain that caused the infections was not the same as the one detected in the plant and that no food-contact surfaces had been contaminated.
On a case-by-case basis, Abbott is issuing cases of a nutrition supplement for people with uncommon metabolic diseases and others. The corporation stated that it is doing so at the FDA's request to assist reduce shortages.
